Enveric Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Enveric Biosciences Inc (ENVB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Enveric Biosciences Inc vs Its Competitors
- Scale: Enveric Biosciences Inc ranks #413 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Enveric Biosciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Enveric Biosciences Inc | - | - | - | No |
| Competitors combined (27) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ENVB Stock Performance relative to its Competitors
ENVB Stock Performance relative to High-Confidence Competitors
ENVB Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Inmed Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Definium Therapeutics Inc | 282.9% | Outperformed |
| 3 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 4 | Evoke Pharma Inc | 282.9% | Outperformed |
| 5 | Alto Neuroscience Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Enveric Biosciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Enveric Biosciences Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Enveric Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Enveric Biosciences Inc |
5.68 | - |
 Indivior Pharmaceuticals Inc |
4,426.16 | 1,376.00 |
 Xenon Pharmaceuticals Inc |
3,901.72 | 13.17 |
 Definium Therapeutics Inc |
3,682.48 | - |
 Ataibeckley Inc |
2,651.54 | 4.47 |
 Avadel Pharmaceuticals Plc |
2,189.59 | 248.76 |
| SUBTOTAL | 20,763.23 | 2,118.58 |
Sign in to see all competitors of Enveric Biosciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Enveric Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Enveric Biosciences Inc's Competitors Named by the Company
Competitive relationships identified from Enveric Biosciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| DeuteRx, LLC | Company report | 85% |
| Neuromity Therapeutics, Inc. | Company report | 85% |
| RIFFIT, Inc. | Company report | 85% |
| GW Pharmaceuticals | Company report | 85% |
| Pfizer | Company report | 85% |
| Genentech | Company report | 85% |
| Next Source Pharmaceuticals | Company report | 85% |
| Arbor Pharmaceuticals | Company report | 85% |
| Merck | Company report | 85% |
| Lutris Pharma | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| Medicines Co | Company report | 85% |
| Cybin Inc | Company report | 85% |
| Zynerba Pharmaceuticals Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Clearmind Medicine Inc | Company report | 85% |
| Compass Pathways Plc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Enveric Biosciences Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Enveric Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Indivior Pharmaceuticals Inc | Reportable 100.00 % |
| Avadel Pharmaceuticals Plc | Reportable 100.00 % |
| Novabridge Biosciences | Oncology 100.00 % |
| Akebia Therapeutics Inc | Reportable 100.00 % |
| Evoke Pharma Inc | Pharmaceutical Products 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Enveric Biosciences Inc .
Enveric Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Enveric Biosciences Inc | 6 | - | -1,454,841 |
| Indivior Pharmaceuticals Inc | 4,426 | 1,376,000 | 451,000 |
| Xenon Pharmaceuticals Inc | 3,902 | 35,597 | -1,105,932 |
| Definium Therapeutics Inc | 3,682 | - | - |
| Ataibeckley Inc | 2,652 | 22,144 | -3,308,347 |
| Avadel Pharmaceuticals Plc | 2,190 | 1,615,338 | -1,805 |
| PEERS TOTAL | 20,758 | 759,892 | -782,655 |
Sign in to see all peers for Enveric Biosciences Inc .
Enveric Biosciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Enveric Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Enveric Biosciences Inc ranks #413 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 413 | Enveric Biosciences Inc | 6 | 0.00 % |
Market cap and industry share for the rest of Enveric Biosciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Enveric Biosciences Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 408 | Alzamend Neuro Inc | 6 | -39.61 % |
| 409 | Fibrobiologics Inc | 6 | -87.30 % |
| 410 | Exicure Inc | 6 | -79.02 % |
| 411 | Oncotelic Therapeutics Inc | 6 | -88.27 % |
| 412 | Tempest Therapeutics Inc | 1,234 | 12.3% |
| 413 | Enveric Biosciences Inc | 6 | -80.11 % |
| 414 | Shuttle Pharmaceuticals Holdings Inc | 1,234 | 12.3% |
| 415 | Soligenix inc | 1,234 | 12.3% |
| 416 | Processa Pharmaceuticals Inc | 1,234 | 12.3% |
| 417 | Integrated Biopharma Inc | 1,234 | 12.3% |
| 418 | Ainos Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Enveric Biosciences Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Enveric Biosciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 0.1x | 26.6x | -26.5x |
| EV / EBITDA | - | 15.9x | - |
| P/B | 1.8x | 4.3x | -2.4x |
| Return on Equity | -168.05 % | industry aggregate | -184.40 % |
| Return on Invested Capital | -84.02 % | -9.83 % (avg) | -74.19 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Enveric Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -11.51 % | -7.17 % | -100.00 % | - | - | - | - | - |
| Operating Margin | -16.62 % | -15.85 % | - | - | - | - | - | - |
| Return on Invested Capital | -17.61 % | -27.57 % | -27.38 % | -101.21 % | -58.85 % | -159.07 % | -110.51 % | -127.76 % |
| P/E | - | - | - | - | - | 304.4x | 5.9x | 0.3x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Enveric Biosciences Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Enveric Biosciences Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Enveric Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Enveric Biosciences Inc's dedicated Suppliers and Customers pages, not here.
Enveric Biosciences Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Enveric Biosciences Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Enveric Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 184.4 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (61.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-2.7% annualized).
Methodology: see Methodology: SWOT Analysis.
Enveric Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Enveric Biosciences Inc | 6.88 | 7.40 | - |
| Indivior Pharmaceuticals Inc | 0.23 | 0.74 | - |
| Xenon Pharmaceuticals Inc | 5.87 | 18.75 | - |
| Definium Therapeutics Inc | 3.23 | 5.69 | 0.10 |
| Ataibeckley Inc | 3.50 | 9.64 | 0.03 |
| Avadel Pharmaceuticals Plc | 1.14 | 2.76 | - |
Sign in to see all peers for Enveric Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Enveric Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Enveric Biosciences Inc | Q2 2026 | - | - |
| Indivior Pharmaceuticals Inc | Q3 2026 | +13.7 % | +226.2 % |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | - |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Ataibeckley Inc | Q2 2026 | +137.0 % | - |
| Avadel Pharmaceuticals Plc | Q3 2025 | +55.3 % | - |
| PEERS TOTAL | +33.2 % | - |
Sign in to see all peers for Enveric Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Enveric Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Enveric Biosciences Inc | Q2 2026 | - | - |
| Indivior Pharmaceuticals Inc | Q3 2026 | -38.6 % | -30.0 % |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | +75.2 % |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Ataibeckley Inc | Q2 2026 | - | - |
| Avadel Pharmaceuticals Plc | Q3 2025 | -33.1 % | - |
Sign in to see all peers for Enveric Biosciences Inc .
Enveric Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Enveric Biosciences Inc | - | - | - |
| Indivior Pharmaceuticals Inc | 36.35% | 108.22% | - |
| Xenon Pharmaceuticals Inc | - | - | - |
| Definium Therapeutics Inc | - | - | - |
| Ataibeckley Inc | - | - | - |
| Avadel Pharmaceuticals Plc | - | - | - |
Sign in to see all peers for Enveric Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Enveric Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Enveric Biosciences Inc | 0.03 | - |
| Indivior Pharmaceuticals Inc | 8.48 | 3.22 |
| Xenon Pharmaceuticals Inc | - | 296.24 |
| Definium Therapeutics Inc | - | - |
| Ataibeckley Inc | - | 592.79 |
| Avadel Pharmaceuticals Plc | - | 8.80 |
| PEERS AVERAGE | - | 9.80 |
Sign in to see all peers for Enveric Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.